SCHEMBL7259137

SCHEMBL7259137

Clc1ccccc1-c1cc2c(NCc3ccccc3)n[nH]c2nn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.50
CYP3A4 P08684 6/20 0.50
CYP2D6 P10635 5/20 0.50
CYP2C19 P33261 5/20 0.50
CLK4 Q9HAZ1 5/20 0.50
MAPK1 P28482 4/20 0.50
TSHR P16473 4/20 0.50
ALOX15 P16050 1/20 0.50
CDC7 O00311 3/20 0.43
GSK3A P49840 4/20 0.42
ALDH1A1 P00352 3/20 0.41
GBA1 P04062 1/20 0.41
USP2 O75604 1/20 0.41
CDK2 P24941 1/20 0.40
FLT4 P35916 1/20 0.40
MAPK8 P45983 1/20 0.40
CLK2 P49760 1/20 0.40
LIMK1 P53667 1/20 0.40
CSNK2A1 P68400 1/20 0.40
CDK5 Q00535 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7256504 0.77 JAK2 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL7255711 0.71 ALPL (0.38) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL7255702 0.71 ALPL (0.38) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL4498618 0.69 GSK3B (0.61) CYP1A2CDC7CDK2CDK1GSK3B
SCHEMBL7132408 0.67 GSK3B (0.60) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL1083779 0.66 CYP1A2 (0.80) CYP1A2CYP3A4CYP2D6CYP2C19CLK4
SCHEMBL31691979 0.66 MAPK1 (0.53) MAPK1CDC7MAPK8CDK1ABL1
SCHEMBL1274224 0.66 MAPK10 (0.61) CDC7MAPK8EGFRAPP
SCHEMBL1375621 0.65 GSK3B (0.64) CDC7ALDH1A1GBA1CDK2MAPK8
SCHEMBL4492484 0.65 GSK3B (0.58) CYP1A2CDC7CDK2CDK1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003080616-A1 PYRAZOLOPYRIDAZINE DERIVATIVES, PROCESS FOR PREPARATION AND USE FOR THE INHIBITION OF GSK-3 GLAXO GROUP LIMITED (GB) 2003-10-02 WO disclosed